Enanta Pharmaceuticals Inc (ENTA) - Total Liabilities

Latest as of March 2026: $198.12 Million USD

Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has total liabilities worth $198.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Enanta Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Enanta Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See ENTA working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Enanta Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Novabase SGPS LS:NBA	Portugal	€67.20 Million
BlackRock California Municipal Income Closed Fund NYSE:BFZ	USA	$275.83 Million
Worldex Industry & Trading Co. Ltd KQ:101160	Korea	₩90.85 Billion
Ratchthani Leasing Public Company Limited BK:THANI	Thailand	฿26.90 Billion
Campine BR:CAMB	Belgium	€107.69 Million
Radiant Logistics Inc NYSE MKT:RLGT	USA	$218.17 Million
El Pollo Loco Holdings Inc NASDAQ:LOCO	USA	$319.82 Million
Race Oncology Ltd AU:RAC	Australia	AU$1.20 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Enanta Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enanta Pharmaceuticals Inc (ENTA) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.84	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.70	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.63	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enanta Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enanta Pharmaceuticals Inc (2011–2025)

The table below shows the annual total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-09-30	$216.01 Million	-12.84%
2024-09-30	$247.84 Million	+0.94%
2023-09-30	$245.54 Million	+314.37%
2022-09-30	$59.26 Million	+43.02%
2021-09-30	$41.43 Million	+17.67%
2020-09-30	$35.21 Million	+28.80%
2019-09-30	$27.34 Million	+33.04%
2018-09-30	$20.55 Million	-17.68%
2017-09-30	$24.96 Million	+120.10%
2016-09-30	$11.34 Million	+15.07%
2015-09-30	$9.86 Million	+45.78%
2014-09-30	$6.76 Million	+3.94%
2013-09-30	$6.50 Million	-20.99%
2012-09-30	$8.23 Million	-94.79%
2011-09-30	$158.06 Million	--

About Enanta Pharmaceuticals Inc

NASDAQ:ENTA USA Biotechnology

Market Cap

$367.55 Million

Market Cap Rank

#14478 Global

#3391 in USA

Share Price

$12.64

Change (1 day)

+4.72%

52-Week Range

$6.49 - $16.85

All Time High

$126.37